Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders

References

• Harrington JW, Allen K. The clinician’s guide to autism. Pediatr Rev. 2014;35:62–78.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
   Google Scholar
• Tsai LY, Ghaziuddin M. DSM-5 ASD moves forward into the past. J Autism Dev Disord. 2014;44:321–330.
   PubMed Web of Science ®Google Scholar
• Lai M-C, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383:896–910.
   PubMed Web of Science ®Google Scholar
• Jure R, Pogonza R, Rapin I. Autism spectrum disorders (ASD) in blind children: very high prevalence, potentially better outlook. J Autism Dev Disord. 2016;46:749–759.
   PubMed Web of Science ®Google Scholar
• Rapin I. Classification of behaviorally defined disorders: biology versus the DSM. J Autism Dev Disord. 2014;44:2661–2666.
   PubMed Web of Science ®Google Scholar
• Ronald A, Hoekstra RA. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am J Med Genet B Neuropsychiatr Genet. 2011;156B:255–274.
   PubMed Web of Science ®Google Scholar
• Silver WG, Rapin I. Neurobiological basis of autism. Pediatr Clin North Am. 2012;59:45–61.
   PubMed Web of Science ®Google Scholar
• Merrick J. Autism spectrum disorders: practical overview for pediatricians. Pediatr Clin North Am. 2012;59:15–17.
   Web of Science ®Google Scholar
• Robinson EB, Neale BM, Hyman SE. Genetic research in autism spectrum disorders. Curr Opin Pediatr. 2015;27(6):685–691.
   PubMed Web of Science ®Google Scholar
• Sandin S, Lichtenstein P, Kuja-Halkola R, et al. The familial risk of autism. JAMA. 2014;311:1770–1777.
   PubMed Web of Science ®Google Scholar
• Chang J, Gilman SR, Chiang AH, et al. Genotype to phenotype relationships in autism spectrum disorders. Nat Neurosci. 2015;18:191–198.
   PubMed Web of Science ®Google Scholar
• Ebisch SJH, Gallese V, Willems RM, et al. Altered intrinsic functional connectivity of anterior and posterior insula regions in high-functioning participants with autism spectrum disorder. Hum Brain Mapp. 2011;32:1013–1028.
   PubMed Web of Science ®Google Scholar
• Fung LK, Mahajan R, Nozzolillo A, et al. Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis. Pediatrics. 2016;137:S124–S135.
   PubMed Web of Science ®Google Scholar
• Peñagarikano O. New therapeutic options for autism spectrum disorder: experimental evidences. Exp Neurobiol. 2015;24:301–311.
   PubMedGoogle Scholar
• Blumberg SJ, Zablotsky B, Avila RM, et al. Diagnosis lost: differences between children who had and who currently have an autism spectrum disorder diagnosis. Autism. 2015;20. pii 1362361315607724.
   PubMedGoogle Scholar
• Christensen DL, Baio J, Braun KVN, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years – autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ. 2016;65:1–23.
   PubMed Web of Science ®Google Scholar
• Nazeer A, Ghaziuddin M. Autism spectrum disorders: clinical features and diagnosis. Pediatr Clin North Am. 2012;59:19–25.
   PubMed Web of Science ®Google Scholar
• Levy SE, Mandell DS, Schultz RT. Autism. Lancet. 2011;374:1627–1638.
   Web of Science ®Google Scholar
• Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am. 2008;17:739–752.
   PubMed Web of Science ®Google Scholar
• McDonnell A, McCreadie M, Mills R, et al. The role of physiological arousal in the management of challenging behaviours in individuals with autistic spectrum disorders. Res Dev Disabil. 2015;36:311–322.
   Web of Science ®Google Scholar
• Matson JL, Neal D, Fodstad JC, et al. The relation of social behaviours and challenging behaviours in infants and toddlers with autism spectrum disorders. Dev Neurorehabil. 2010;13:164–169.
   PubMed Web of Science ®Google Scholar
• Matson JL, Sipes M, Fodstad JC, et al. Issues in the management of challenging behaviours of adults with autism spectrum disorder. CNS Drugs. 2011;25:597–606.
   PubMed Web of Science ®Google Scholar
• Hill AP, Zuckerman KE, Hagen AD, et al. Aggressive behavior problems in children with autism spectrum disorders: prevalence and correlates in a large clinical sample. Res Autism Spectr Disord. 2014;8:1121–1133.
   PubMed Web of Science ®Google Scholar
• Aman MG, Singh NN, Stewart AW, et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–491.
   PubMedGoogle Scholar
• Jang J, Matson JL, Williams LW, et al. Rates of comorbid symptoms in children with ASD, ADHD, and comorbid ASD and ADHD. Res Dev Disabil. 2013;34:2369–2378.
   PubMed Web of Science ®Google Scholar
• Buescher AVS, Cidav Z, Knapp M, et al. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168:721–728.
   PubMed Web of Science ®Google Scholar
• Esbensen AJ, Greenberg JS, Seltzer MM, et al. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord. 2012;39:1339–1349.
   Web of Science ®Google Scholar
• Coury DL, Anagnostou E, Manning-Courtney P, et al. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics. 2012;130:S69–S76.
   PubMed Web of Science ®Google Scholar
• Malone RP, Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism. Drugs. 2009;69:535–548.
   PubMed Web of Science ®Google Scholar
• Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2014;53:237–257.
   PubMed Web of Science ®Google Scholar
• Dove D, Warren Z, McPheeters ML, et al. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics. 2012;130:717–726.
   PubMed Web of Science ®Google Scholar
• Lin J-D. Medical care burden of children with autism spectrum disorders. Rev J Autism Dev Disord. 2014;1:242–247.
   Google Scholar
• Almandil NB, Liu Y, Murray ML, et al. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15:139–150.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Autism: the management and support of children and young people on the autism spectrum. CG 170. London: National Institute for Health and Care Excellence; 2013.
   Google Scholar
• De Fazio P, Girardi P, Maina G. Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group. Clin Drug Investig. 2010;30:827–841.
   PubMed Web of Science ®Google Scholar
• Zheng W, Li X-B, Xiang Y-Q, et al. Aripiprazole for Tourette’s syndrome: a systematic review and meta-analysis. Hum Psychopharmacol. 2016;31:11–18.
   PubMed Web of Science ®Google Scholar
• Habibi N, Dodangi N, Nazeri A. Efficacy and safety of aripiprazole for treatment of irritability in children with autistic disorder: an open-label study. Iran J Med Sci. 2014;40:548–459.
   Google Scholar
• Deb S, Farmah BK, Arshad E. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder – a systematic review. Res Dev Disabil. 2014;35:711–725.
   PubMed Web of Science ®Google Scholar
• Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18:250–260.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179–187.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110–1119.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–1540.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72:1270–1276.
   PubMed Web of Science ®Google Scholar
• Findling RL, Mankoski R, Timko K, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014;75:22–30.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:185–192.
   PubMed Web of Science ®Google Scholar
• Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012 May 16;(5):CD009043. doi:10.1002/14651858.CD009043.pub3.
   Google Scholar
• Robb AS, Andersson C, Bellocchio EE, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord. 2011;13. pii PCC.10m01008.
   PubMedGoogle Scholar
• Jensen KG, Juul K, Fink-Jensen A, et al. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry. 2015;54:25–36.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–1773.
   PubMed Web of Science ®Google Scholar
• Mankoski R, Stockton G, Manos G, et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol. 2013;23:572–576.
   PubMed Web of Science ®Google Scholar
• Guinchat V, Cravero C, Diaz L. Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement. Res Dev Disabil. 2015 Mar;38:242–255.
   PubMed Web of Science ®Google Scholar
• McGuire K, Fung LK, Hagopian L, et al. Irritability and problem behavior in autism spectrum disorder: a practice pathway for pediatric primary care. Pediatrics. 2016;137:S136–S148.
   PubMed Web of Science ®Google Scholar
• Varni JW, Handen BL, Corey-Lisle PK, et al. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther. 2012;34:980–992.
   PubMed Web of Science ®Google Scholar